Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2019.01031
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

PET Radiopharmaceuticals in Europe: Current Use and Data Relevant for the Formulation of Summaries of Product Characteristics (SPCs)

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
1995English

Optimization of Dalbavancin in Patients With Hepatic or Renal Impairment

Pharmacology & Pharmacy
2020English

Characteristics and Course of Patients Treated With Kampo Medicine in the Department of General Medicine

Journal of General and Family Medicine
2020English

Pharmacokinetic Study of Osimertinib in Cancer Patients With Mild or Moderate Hepatic Impairment

Journal of Pharmacology and Experimental Therapeutics
Molecular MedicinePharmacology
2019English

Pharmacokinetics and Safety of a Single Dose of Stavudine (D4T) in Patients With Severe Hepatic Impairment.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

Evaluation of Deficiencies in Current Discharge Summaries for Dialysis Patients in Canada

Journal of Multidisciplinary Healthcare
MedicineNursing
2012English

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Journal of Clinical Pharmacology
Pharmacology
2018English

Use of Computer Stimulating Programs in Patients With Post-Stroke Cognitive Impairment

Nevrologiya, Neiropsikhiatriya, Psikhosomatika
PsychiatryClinical PsychologyMental HealthNeurology
2017English

The Prevalence of Natural Health Product Use in Patients With Acute Cardiovascular Disease

PLoS ONE
Multidisciplinary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy